Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities

Real‐world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

“…The results of this large‐scale, nationwide observational cohort study confirmed the efficacy and safety of SOF + RBV in real‐world situations. The SVR12 was 96.8% in the intention‐to‐treat population and 97.6% in the per‐protocol population, which was similar to other Japanese real‐world data and higher than European and North American real‐world data . Multivariate analysis revealed that advanced fibrosis and IFN experience independently attenuated the SVR rate.…”

“…Recent real‐world studies suggested that SVR decreases as the proportion of cirrhotic patients included in cohorts increases . The role of RBV adherence might affect SVR.…”

ITPA gene variation and ribavirin‐induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin

“…[7][8][9][10][11] However, RBV-induced hemolytic anemia is one of the most troublesome side-effects, resulting in dose reduction or sometimes premature withdrawal of therapy. 10,12 Because anemia often exists before initiating therapy, particularly in the elderly, women, or patients with cirrhosis, there may be hesitation in using RBV to treat HCV in such individuals.…”

Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients

“…Progression of liver fibrosis is strongly associated with IFN‐based therapy . In contrast, the effect of liver fibrosis on IFN‐free DAA treatment is controversial . We and another group have also reported that virological response rates were lower in patients with progression of liver fibrosis in real‐world studies of sofosbuvir plus ribavirin and sofosbuvir/ledipasvir therapies for HCV genotypes 2 and 1, respectively .…”